Criteria for fairly allocating scarce health-care resources to genetic tests: Which matter most

European Journal of Human Genetics

Volumn 22, Issue 1, 2014, Pages 25-31

  Rogowski, Wolf H ^a,b   Grosse, Scott D ^c   Schmidtke, Jörg ^d   Marckmann, Georg ^e  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e UNIVERSITY OF MUNICH   (Germany)

Author keywords

costs and cost analysis; ethics; genetic testing; health care prioritization; resource allocation

Indexed keywords

ARTICLE; BUDGET; CLINICAL PRACTICE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DECISION MAKING; FIRST DEGREE RELATIVE; GENETIC SCREENING; HEALTH CARE; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE SYSTEM; HEMOCHROMATOSIS; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; HUNTINGTON CHOREA; LIFE EXPECTANCY; MEDICAL TECHNOLOGY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RESOURCE ALLOCATION; WORLD HEALTH ORGANIZATION; ECONOMICS; EUROPE; HEALTH CARE DELIVERY; SOCIAL BEHAVIOR;

DECISION MAKING; DELIVERY OF HEALTH CARE; EUROPE; GENETIC TESTING; HUMANS; SOCIAL RESPONSIBILITY;

EID: 84890788439     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2013.172     Document Type: Article

References (55)

1. Schmidtke J, Pabst B, Nippert I: DNA-based genetic testing is rising steeply in a national health care system with open access to services: a survey of genetic test use in Germany, 1996-2002. Genet Test 2005; 9: 80-84.
2. Javaher P, Kaariainen H, Kristoffersson U et al: EuroGentest: DNA-based testing for heritable disorders in Europe. Community Genet 2008; 11: 75-120.
3. Rogowski W: Genetic screening by DNA technology. A systematic review of health economic evidence. Int J Technol Assess Health Care 2006; 22: 327-337.
4. Rogowski W: Current impact of gene technology on healthcare. A map of economic assessments. Health Policy 2007; 80: 340-357.
5. Mardis ER: The $1,000 genome, the $100,000 analysis? Genome Med 2010; 2: 84.
6. Krawczak M, Caliebe A, Croucher PJ, Schmidtke J: On the testing load incurred by cascade genetic carrier screening for Mendelian disorders: a brief report. Genet Test 2007; 11: 417-419.
7. Adair A, Hyde-Lay R, Einsiedel E, Caulfield T: Technology assessment and resource allocation for predictive genetic testing: a study of the perspectives of Canadian genetic health care providers. BMC Med Ethics 2009; 10: 6.
8. Marmot M, Allen J, Bell R, Bloomer E, Goldblatt P: WHO European review of social determinants of health and the health divide. Lancet 2012; 380: 1011-1029.
9. van Doorslaer E, Koolman X, Jones AM: Explaining income-related inequalities in doctor utilisation in Europe. Health Econ 2004; 13: 629-647.
10. Huster S: Soziale Gesundheitsgerechtigkeit: sparen, umverteilen, vorsorgen?. Berlin: Wagenbach, 2011.
11. Giacomini M, Miller F, Browman G: Confronting the 'gray zones' of technology assessment: evaluating genetic testing services for public insurance coverage in Canada. Int J Technol Assess 2003; 19: 301-316.
12. Rogowski WH, Hartz SC, John JH: Clearing up the hazy road from bench to bedside: a framework for integrating the fourth hurdle into translational medicine. BMC Health Serv Res 2008; 8: 1-12.
13. Broqvist M, Elgstrand MB, Carlsson P, Eklund K, Jakobsson A: National Model for Transparent Prioritisation in Swedish Health Care: Revised Version: National Center for Priority Setting in Healthcare 2011.
14. Carlsson J: National and regional priority setting in Swedish health care: experiences from cardiology. Z Evid Fortbild Qual Gesundh wesen 2012; 106: 435-442.
15. Schmidtke J, Cassiman JJ: The EuroGentest clinical utility gene cards. Eur J Hum Genet 2010; 18: 1068.
16. Sequeiros J, Paneque M, Guimaraes B et al: The wide variation of definitions of genetic testing in international recommendations, guidelines and reports. J Community Genet 2012; 3: 113-124.
17. Eisenberg VH, Schenker JJ: The moral aspects of prenatal diagnosis. Eur J Obstet Gynecol Reprod Biol 1997; 72: 35-45.
18. West R: Ethical aspects of genetic disease and genetic counselling. J Med Ethics 1988; 14: 194-197.
19. Johnson SR, Elkins TE: Ethical issues in prenatal diagnosis. Clin Obstet Gynecol 1988; 31: 408-417.
20. Grosse SD, Rogowski WH, Ross LF, Cornel MC, Dondorp WJ, Khoury MJ: Population screening for genetic disorders in the 21st century: evidence, economics, and ethics. Public Health Genomics 2010; 13: 106-115.
21. Persad G, Wertheimer A, Emanuel EJ: Principles for allocation of scarce medical interventions. Lancet 2009; 373: 423-431.
22. Williams A: Intergenerational equity: an exploration of the 'fair innings' argument. Health Econ 1997; 6: 117-132.
23. National Centre for Prioritiy Setting in Health Care. PrioriteringsCentrum: Resolving health care's difficult choices. survey of priority setting in Sweden and an analysis of principles and guidelines on priorities in health care. Rapport 2008:2. Linköping: National Centre for Prioritiy Setting in Health Care, 2008.
24. Cookson R, Dolan P: Principles of justice in health care rationing. J Med Ethics 2000; 26: 323-329.
25. Grosse SD, Wordsworth S, Payne K: Economic methods for valuing the outcomes of genetic testing: beyond cost-effectiveness analysis. Genet Med 2008; 10: 648-654.
26. Payne K, Nicholls S, McAllister M, Macleod R, Donnai D, Davies LM: Outcome measurement in clinical genetics services: a systematic review of validated measures. Value Health 2008; 11: 497-508.
27. Rogowski WH, Grosse SD, Khoury MJ: Challenges of translating genetic tests into clinical and public health practice. Nat Rev Genet 2009; 10: 489-495.
28. Garber AM: Cost-effectiveness and evidence evaluation as criteria for coverage policy. Health Aff (Millwood) 2004; Suppl Web Exclusives: W4-284-W4-296.
29. Kenny N, Joffres C: An ethical analysis of international health priority-setting. Health Care Anal 2008; 16: 145-160.
30. Marckmann G: Priorisierung im Gesundheitswesen: Was können wir aus den internationalen Erfahrungen lernen? Z Evid Fortbild Qual Gesundh wesen 2009; 85-91.
31. Hurley J: An overview of the normative economics of the health sector; in Culyer A, Newhouse JP (eds). Handbook of Health Economics. Elsevier Science BV, 2000; Vol 1.
32. Arrow KJ: Uncertainty and the welfare economics of medical care. Am Econ Rev 1963; 53: 141-149.
33. Boadway R, Bruce N: Welfare Economics. Oxford [u.a.]: Blackwell, 1984.
34. Rogowski WH, Grosse SD, John J et al: Points to consider in assessing and appraising predictive genetic tests. J Community Genet 2010; 1: 185-194.
35. Sen A: The possibility of social choice. Am Econ Rev 1999; 89: 349-378.
36. Brouwer WB, Culyer AJ, van Exel NJ, Rutten FF: Welfarism vs extra-welfarism. J Health Econ 2008; 27: 325-338.
37. Claxton K, Briggs A, Buxton MJ et al: Value based pricing for NHS drugs: an opportunity not to be missed? BMJ 2008; 336: 251-254.
38. Brazier J, Ratcliffe J, Salomon JA, Tsuchiya A: Measuring and Valuing Health Benefits for Economic Evaluation, 1st edn. Oxford [u.a.]: Oxford University Press, 2007.
39. Baltussen R, Niessen L: Priority setting of health interventions: the need for multicriteria decision analysis. Cost Eff Resour Alloc 2006; 4: 14.
40. Klonschinski A, Lübbe W: QALYs and fairness: health economic approaches to the fairness issue and their problems. Gesundheitswesen 2011; 73: 688-695.
41. National Institute for Health and Clinical Excellence: Guide to the Methods of Technology Appraisal, Vol 2008: London: NICE, 2008.
42. Minhas R, Humphries SE, Qureshi N, Neil HA: Controversies in familial hypercholesterolaemia: recommendations of the NICE Guideline Development Group for the identification and management of familial hypercholesterolaemia. Heart 2009; 95: 584-587, discussion 587-591.
43. Kroese M, Burton H, Whittaker J, Lakshman R, Alberg C: A framework for the prioritization of investment in the provision of genetic tests. Public Health Genom 2010; 13: 538-543.
44. Anell A: Priority setting for pharmaceuticals. The use of health economic evidence by reimbursement and clinical guidance committees. Eur J Health Econ 2004; 5: 28-35.
45. Kaye J: The regulation of direct-to-consumer genetic tests. Hum Mol Genet 2008; 17: R180-R183.
46. Wasson K, Cook ED, Helzlsouer K: Direct-to-consumer online genetic testing and the four principles: an analysis of the ethical issues. Ethics Med 2006; 22: 83-91.
47. McGuire AL, Burke W: An unwelcome side effect of direct-to-consumer personal genome testing: raiding the medical commons. JAMA 2008; 300: 2669-2671.
48. Culyer AJ, Wagstaff A: Equity and equality in health and health care. J Health Econ 1993; 12: 431-457.
49. Guindo LA, Wagner M, Baltussen R et al: From efficacy to equity: literature review of decision criteria for resource allocation and healthcare decisionmaking. Cost Eff Resour Alloc 2012; 10: 9.
50. Wailoo A, Tsuchiya A, McCabe C: Weighting must wait: incorporating equity concerns into cost-effectiveness analysis may take longer than expected. Pharmacoeconomics 2009; 27: 983-989.
51. Rogowski WH: The cost-effectiveness of screening for hereditary hemochromatosis in Germany: a remodeling study. Med Decis Making 2009; 29: 224-238.
52. Otlowski M, Taylor S, Bombard Y: Genetic discrimination: international perspectives. Annu Rev Genom Hum Genet 2012; 13: 433-454.
53. Baily MA: Ethics and newborn genetic screening: new technologies, new challenges; in: Baily MA, Murray TH (eds) Ethics and Newborn Genetic Screening: New Technologies, New Challenges. Baltimore, MD, USA: Johns Hopkins University Press, 2009.
54. Daniels N, Sabin J: The ethics of accountability in managed care reform. Health Aff (Millwood) 1998; 17: 50-64.
55. Severin F, Schmidtke J, Muhlbacher A, Rogowski WH: Eliciting preferences for priority setting in genetic testing: a pilot study comparing best-worst scaling and discretechoice experiments. Eur J Hum Genet 2013; 21: 1202-1208.